<DOC>
	<DOCNO>NCT00954005</DOCNO>
	<brief_summary>The purpose phase I part determine tolerability , initial safety profile maximum tolerate dose oxaliplatin combination gemcitabine indolent lymphoma . In phase II part investigator want estimate activity gemcitabine oxaliplatin combination rituximab patient relapsed/refractory indolent lymphoma .</brief_summary>
	<brief_title>Study With Rituximab-Gemcitabine/Oxaliplatin Relapsed Indolent Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Need therapy patient relapsed/refractory patient Histological proven diagnosis indolent Bcell lymphoma accord World Health Organization ( WHO ) classification belong one follow entity : follicular lymphoma mantle cell lymphoma lymphoplasmacytic lymphoma nodal splenic marginal zone lymphoma measurable disease lymphoma specific therapy last four week WHO performance grade 0 , 1 2 Exclusion Criteria Patients suitable high dose therapy Transformation high grade lymphoma Leukocytes &lt; 1,5/nl platelet &lt; 100/nl ( except due lymphoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>relapse indolent lymphoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>rituximab</keyword>
</DOC>